Teplizumab on Word of Mouth


Great personal news: my piece in Popular Science about anti-CD3 monoclonal antibodies (currently best known as teplizumab) and Type 1 diabetes was just featured on the New Hampshire Public Radio show Word of Mouth. (You can read about the segment, and listen to the interview, here.)

It’s always great to get to talk about something you’ve worked hard on, but I found myself getting surprisingly nervous before this particular interview. Part of it was my typical worry that I am somehow going to lose my ability to speak English the moment the host asks me a question. (Words? What are words?) But this time, there was an added challenge: talking intelligently about immunology — an area in which I am not an expert — about a complicated subject in a way that the general public could understand. (You guys will have to let me know how I did!) Luckily, words did indeed come out of my mouth, and by the end of the segment,  I was actually enjoying myself. But it’s interesting to feel your body pumping up the adrenaline — and I have a feeling that may have had something to do with the fact that my blood sugar went high this morning and has only now come back down.

And that’s very good news: it’s 2:15 in the afternoon, and I haven’t eaten lunch.

Notify of
Inline Feedbacks
View all comments
Copyright © 2009-2021 Diabetes Media Foundation, All Rights Reserved.
ASweetLife™ is a trademark of the Diabetes Media Foundation, All Rights Reserved.
Would love your thoughts, please comment.x